Selecting an appropriate biomonitoring strategy to evaluate dermal exposure to opioid narcotic analgesics in pharmaceutical production workers

Occupational and Environmental Medicine

Volumn 67, Issue 7, 2010, Pages 464-470

  Van Nimmen, N F J ^a   Poels, K L C ^a   Severi, M J ^a   Godderis, L ^a,b   Veulemans, H A F ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b EXTERNAL SERVICE FOR PREVENTION AND PROTECTION AT WORK   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; NARCOTIC ANALGESIC AGENT; OPIATE;

ARTICLE; BIOLOGICAL MONITORING; CLINICAL ARTICLE; CONTAMINATION; CORRELATION ANALYSIS; HUMAN; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; SKIN; URINALYSIS; URINARY EXCRETION; WORKER;

ADULT; AIR POLLUTANTS, OCCUPATIONAL; ANALGESICS, OPIOID; BIOLOGICAL MARKERS; DRUG INDUSTRY; ENVIRONMENTAL MONITORING; FENTANYL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NARCOTICS; OCCUPATIONAL EXPOSURE; SKIN ABSORPTION;

EID: 77955601944     PISSN: 13510711     EISSN: 14707926     Source Type: Journal    
DOI: 10.1136/oem.2009.050583     Document Type: Article

References (15)

1. Binks SP. Occupational toxicology and the control of exposure to pharmaceutical agents at work. Occup Med (Lond) 2003;53:363-70.
2. Van Nimmen NF, Poels KL, Veulemans HA. Identification of exposure pathways for opioid narcotic analgesics in pharmaceutical production workers. Ann Occup Hyg 2006;50:665-77.
3. Drexler H. Skin protection and percutaneous absorption of chemical hazards. Int Arch Occup Environ Health 2003;76:359-61.
4. Van Nimmen NF, Poels KL, Veulemans HA. Highly sensitive gas chromatographic-mass spectrometric screening method for the determination of picogram levels of fentanyl, sufentanil and alfentanil and their major metabolites in urine of opioid exposed workers. J Chromatogr B Analyt Technol Biomed Life Sci 2004;804:375-87.
5. American Conference of Governmental Industrial Hygienists (ACGIH®). In: 2009 TLVs® and BEIs®: Threshold Limit Values for chemical substances and physical agents & Biological Exposure Indices. Cincinnati: ACGIH, 2009: 97.
6. Meuldermans W, Lavrijsen K, Heykants J. The metabolism of the narcotic analgesics phenoperidine, fentanyl, sufentanil and alfentanil. In: Chauvin M, ed. Les Morphiniques. Arnette, Paris: 1993: 85-96.
7. Hines CJ, Deddens JA, Striley CAF, et al. Biological monitoring for selected herbicide biomarkers in the urine of exposed custom applicators: application of mixed-effect models. Ann Occup Hyg 2003;47:503-17.
8. Burdorf A. Identification of determinants of exposure: consequences for measurement and control strategies. Occup Environ Med 2005;62:344-50.
9. Gueorguieva R, Krystal JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 2004;61:310-17.
10. Peretz C, Goren A, Smid T, et al. Application of mixed-effects models for exposure assessment. Ann Occup Hyg 2002;46:69-77.
11. McClean MD, Rinehart RD, Ngo L, et al. Urinary 1-hydroxypyrene and polycyclic aromatic hydrocarbon exposure among asphalt paving workers. Ann Occup Hyg 2004;48:565-78.
12. Scholz J, Steinfath M, Schulz M. Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Clin Pharmacokinet 1996;31:275-92.
13. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet 2000;38:59-89.
14. Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001;61:2289-307.
15. Van Nimmen NF, Poels KL, Menten JJ, et al. Fentanyl transdermal absorption linked to pharmaco-kinetic characteristics in patients undergoing palliative care. J Clin Pharmacol 2009. In press.